Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Depreciation & Amortization - Total (2016 - 2020)

Historic Depreciation & Amortization - Total for Ani Pharmaceuticals (ANIP) over the last 9 years, with Q4 2020 value amounting to $1.3 million.

  • Ani Pharmaceuticals' Depreciation & Amortization - Total rose 833.33% to $1.3 million in Q4 2020 from the same period last year, while for Sep 2021 it was $1.3 million, marking a year-over-year decrease of 7291.67%. This contributed to the annual value of $7.4 million for FY2024, which is 133.33% down from last year.
  • According to the latest figures from Q4 2020, Ani Pharmaceuticals' Depreciation & Amortization - Total is $1.3 million, which was up 833.33% from $1.2 million recorded in Q3 2020.
  • Ani Pharmaceuticals' Depreciation & Amortization - Total's 5-year high stood at $1.3 million during Q4 2020, with a 5-year trough of $200000.0 in Q1 2016.
  • In the last 5 years, Ani Pharmaceuticals' Depreciation & Amortization - Total had a median value of $500000.0 in 2018 and averaged $680000.0.
  • In the last 5 years, Ani Pharmaceuticals' Depreciation & Amortization - Total changed by 0.0% in 2016 and then soared by 30000.0% in 2019.
  • Ani Pharmaceuticals' Depreciation & Amortization - Total (Quarter) stood at $200000.0 in 2016, then surged by 50.0% to $300000.0 in 2017, then surged by 166.67% to $800000.0 in 2018, then surged by 50.0% to $1.2 million in 2019, then rose by 8.33% to $1.3 million in 2020.
  • Its last three reported values are $1.3 million in Q4 2020, $1.2 million for Q3 2020, and $1.2 million during Q2 2020.